Literature DB >> 21918037

Characterization of the expression and activity of carboxylesterases 1 and 2 from the beagle dog, cynomolgus monkey, and human.

Eric T Williams1, James A Bacon, David M Bender, Jennifer J Lowinger, Wen-Kai Guo, Mariam E Ehsani, Xiliang Wang, He Wang, Yue-Wei Qian, Kenneth J Ruterbories, Steven A Wrighton, Everett J Perkins.   

Abstract

The carboxylesterases (CESs) are a family of serine hydrolases that hydrolyze compounds containing an ester, amide, or thioester. In humans, two dominant forms, CES1 and CES2, are highly expressed in organs of first-pass metabolism and play an important role in xenobiotic metabolism. The current study was conducted to better understand species-related differences in substrate selectivity and tissue expression of these enzymes. To elucidate potential similarities and differences among these enzymes, a series of 4-nitrophenyl esters and a series of gemcitabine prodrugs were evaluated using enzyme kinetics as substrates of expressed and purified CESs from beagle dog, cynomolgus monkey, and human genes. For the substrates examined, human and monkey CES2 more efficiently catalyzed hydrolysis compared with CES1, whereas CES1 was the more efficient enzyme in dog. Quantitative real-time polymerase chain reaction and Western blot analyses indicate that the pattern of CES tissue expression in monkey is similar to that of human, but the CES expression in dog is unique, with no detectable expression of CES in the intestine. Loperamide, a selective human CES2 inhibitor, was also found to be a CES2-selective inhibitor in both dog and monkey. This is the first study to examine substrate specificity among dog, human, and monkey CESs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21918037     DOI: 10.1124/dmd.111.041335

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  18 in total

1.  A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834.

Authors:  Jasleen K Sodhi; Susan Wong; Donald S Kirkpatrick; Lichuan Liu; S Cyrus Khojasteh; Cornelis E C A Hop; John T Barr; Jeffrey P Jones; Jason S Halladay
Journal:  Drug Metab Dispos       Date:  2015-04-06       Impact factor: 3.922

Review 2.  Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.

Authors:  Upendra A Argikar; Philip M Potter; J Matthew Hutzler; Punit H Marathe
Journal:  AAPS J       Date:  2016-08-05       Impact factor: 4.009

3.  Physiologically Based Absorption Modeling to Design Extended-Release Clinical Products for an Ester Prodrug.

Authors:  Xuan Ding; Jeffrey S Day; David C Sperry
Journal:  AAPS J       Date:  2016-07-12       Impact factor: 4.009

4.  Metabolism and pharmacokinetics of the anti-hepatitis C virus nucleotide prodrug GS-6620.

Authors:  Eisuke Murakami; Ting Wang; Darius Babusis; Eve-Irene Lepist; Dorothea Sauer; Yeojin Park; Jennifer E Vela; Robert Shih; Gabriel Birkus; Dimitrios Stefanidis; Choung U Kim; Aesop Cho; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

Review 5.  The expanding role of prodrugs in contemporary drug design and development.

Authors:  Jarkko Rautio; Nicholas A Meanwell; Li Di; Michael J Hageman
Journal:  Nat Rev Drug Discov       Date:  2018-04-27       Impact factor: 84.694

6.  Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamine-induced pulmonary arterial hypertension.

Authors:  Mark E Orcholski; Artyom Khurshudyan; Elya A Shamskhou; Ke Yuan; Ian Y Chen; Sean D Kodani; Christophe Morisseau; Bruce D Hammock; Ellen M Hong; Ludmila Alexandrova; Tero-Pekka Alastalo; Gerald Berry; Roham T Zamanian; Vinicio A de Jesus Perez
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-05-04       Impact factor: 5.464

7.  Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity.

Authors:  Chi C Wong; Ka-Wing Cheng; Gang Xie; Dingying Zhou; Cai-Hua Zhu; Panayiotis P Constantinides; Basil Rigas
Journal:  J Pharmacol Exp Ther       Date:  2011-11-15       Impact factor: 4.030

8.  Hepatic carboxylesterases are differentially regulated in PPARα-null mice treated with perfluorooctanoic acid.

Authors:  Xia Wen; Angela A Baker; Curtis D Klaassen; J Christopher Corton; Jason R Richardson; Lauren M Aleksunes
Journal:  Toxicology       Date:  2019-01-24       Impact factor: 4.221

9.  Interspecies Differences in the Metabolism of a Multiester Prodrug by Carboxylesterases.

Authors:  Jing Fu; Erik Pacyniak; Marina G D Leed; Matthew P Sadgrove; Lesley Marson; Michael Jay
Journal:  J Pharm Sci       Date:  2016-01-12       Impact factor: 3.534

10.  Cholecalciferol-PEG Conjugate Based Nanomicelles of Doxorubicin for Treatment of Triple-Negative Breast Cancer.

Authors:  Shallu Kutlehria; Gautam Behl; Ketan Patel; Ravi Doddapaneni; Imran Vhora; Nusrat Chowdhury; Arvind Bagde; Mandip Singh
Journal:  AAPS PharmSciTech       Date:  2017-10-10       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.